Biogen Inc (NAS:BIIB) Stock News, Headlines & Updates
Biogen Inc Stock News from GuruFocus
- 1
- 2
- 3
Jul 01, 2025
Biogen Inc (BIIB) Trading 4.67% Higher on Jul 1
GuruFocus News • 12:07pm
Jun 30, 2025
Biogen (BIIB) Initiates Phase 3 Trial for Kidney Disease Treatment
GuruFocus News • 10:55am
Biogen Inc (BIIB) Launches Phase 3 Study for Felzartamab in Treating Rare Kidney Disease | BIIB stock news
GuruFocus News • 7:08am
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Marketwired • 7:00am
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy | BIIB Stock News
GuruFocus News • 6:45am
Jun 27, 2025
Biogen (BIIB) Unveils Promising Spinraza Data
GuruFocus News • 1:55pm
Biogen Inc (BIIB) Announces Promising Data on Nusinersen for SMA Treatment | BIIB stock news
GuruFocus News • 11:03am
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Marketwired • 10:00am
Biogen (BIIB) Highlights Promising Data on Nusinersen for SMA Treatment | BIIB Stock News
GuruFocus News • 9:16am
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | BIIB Stock News
GuruFocus News • 9:15am
Biogen (BIIB) Maintains Outperform Rating with Price Target of $213 | BIIB Stock News
GuruFocus News • 8:02am
Jun 26, 2025
BIIB: Analyst Reiterates Buy Rating and Maintains Price Target | BIIB Stock News
GuruFocus News • 7:30am
Jun 25, 2025
Biogen (BIIB) Advances SMA Treatment to Key Study Phase | BIIB Stock News
GuruFocus News • 1:30pm
Biogen (BIIB) Receives Price Target Upgrade from RBC Capital | BIIB Stock News
GuruFocus News • 9:34am
Biogen (BIIB) Receives Increased Price Target from RBC Capital | BIIB Stock News
GuruFocus News • 8:02am
Biogen Inc (BIIB) Announces Promising Phase 1 Results for Salanersen in Treating Spinal Muscular Atrophy | BIIB stock news
GuruFocus News • 7:06am
Biogen (BIIB) Reports Positive Phase 1 Results for Salanersen in SMA Treatment | BIIB Stock News
GuruFocus News • 7:01am
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Marketwired • 7:00am
Biogen (BIIB) Reports Promising Phase 1 Results for Salanersen in SMA Treatment | BIIB Stock News
GuruFocus News • 6:47am
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | BIIB Stock News
GuruFocus News • 6:45am
Jun 24, 2025
Biogen Inc. (BIIB) Announces Results of 2025 Annual Meeting of Stockholders
GuruFocus News • 7:00pm
Jun 18, 2025
Biogen Inc (BIIB) Initiates Phase 3 BRAVE Study for Pediatric Friedreich Ataxia Treatment | BIIB stock news
GuruFocus News • 8:16am
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Marketwired • 7:00am
Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxolone | BIIB Stock News
GuruFocus News • 6:48am
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News
GuruFocus News • 6:47am
Jun 17, 2025
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News
GuruFocus News • 9:15am
Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News
GuruFocus News • 6:33am
Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News
GuruFocus News • 6:33am
Jun 16, 2025
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News
GuruFocus News • 6:31am
Jun 12, 2025
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News
GuruFocus News • 12:31pm
Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News
GuruFocus News • 9:30am
Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News
GuruFocus News • 6:01am
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News
GuruFocus News • 5:45am
Biogen (BIIB) Shows Promise in Lupus Treatment Study | BIIB Stock News
GuruFocus News • 4:30am
Biogen Inc (BIIB) Announces Promising Phase 3 Results for Dapirolizumab Pegol in Treating Systemic Lupus Erythematosus | BIIB stock news
GuruFocus News • 2:02am
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Marketwired • 1:00am
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity | BIIB Stock News
GuruFocus News • 12:15am
Jun 11, 2025
Biogen (BIIB) Explores New Frontiers with Felzartamab in Kidney Disease | BIIB Stock News
GuruFocus News • 9:17am
Jun 03, 2025
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
GuruFocus News • 10:02am
May 30, 2025
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
GuruFocus News • 10:01am
- 1
- 2
- 3
Show
Entries
Headlines
Total 0- 1
No recent news